Nasdaq
$8.22▲ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $8.61BShares out 10.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.14After-hours26.10.15 06:198-KKey event#●●●#●●●
ImmunityBio, Inc.Bullish
On October 14, 2026, ImmunityBio announced that the U.S. FDA expanded the approved indication for ANKTIVA in combination with BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors. This approval broadens the eligible patient population beyond those with carcinoma in situ (CIS), marking the first FDA-approved therapy for both CIS and papillary-only disease in this setting.…more
$8.22+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 07:064Ownership
ImmunityBio, Inc.
Insider Barry J. Simon of ImmunityBio, Inc. filed a Form 4 report on October 6, 2026, regarding changes in beneficial ownership of securities as of October 5, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$8.22+0.06%vs prev closeView filingShare - 10.6After-hours26.10.07 07:054Ownership
ImmunityBio, Inc.
Insider Cheryl Cohen of ImmunityBio, Inc. reported a change in beneficial ownership of securities as of October 2, 2026. This filing serves as a standard disclosure of insider equity movement and does not involve material corporate events such as capital raising or delisting.…more
$8.22+0.06%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:38#●●●#●●●
ImmunityBio Sets November 2026 for ANKTIVA Bladder Cancer Trial Results…more
ImmunityBio expects to report topline results for its ANKTIVA combination therapy in BCG-naïve NMIBC patients by November 2026. The company remains on track to submit a supplemental Biologics License Application to the FDA in the fourth quarter of 2026.…more
$8.22+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.21 20:37
●●●●●●●● ●●●●● ●●●●●●
ImmunityBio has completed the database lock for its Phase 3 trial of ANKTIVA in bladder cancer patients and has begun final data analysis. The company expects to report topline results in November 2026 and remains on track to submit a supplemental BLA to the FDA by the end of 2026.…more
$8.22+0.06%vs prev closeShareBenzinga - 5d agoRegular26.10.20 00:52
●●●●●●●● ●●●●● ●●●●●●
ImmunityBio's bladder cancer treatment, ANKTIVA, demonstrated a 71% complete response rate and strong survival metrics in recent long-term clinical studies. These findings reinforce the clinical evidence for the FDA-approved therapy and support its potential for continued market adoption.…more
$8.22+0.06%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report